The CINCH-FMR Post-Market Registry: Percutaneous Repair in Functional Mitral Regurgitation (CINCH-FMR)

This is a retrospective and prospective, multi-center, post-market observational registry study. The primary objective of this post market registry is to continue to evaluate the long term safety and performance of the Carillon® Mitral Contour System® (CMCS) in a commercial (post market) setting.

Study Overview

• Status: Enrolling by invitation
• Conditions: Mitral Regurgitation; Functional Mitral Regurgitation
• Intervention / Treatment: Device: Carillon Mitral Contour System

Detailed Description

There are more than 22 million people worldwide with heart failure, including 5.3 million in the United States . Functional mitral regurgitation (MR), leakage of the mitral valve due to dilation of the left ventricle and annulus, occurs as a consequence of Heart Failure. Cardiac Dimensions has developed proprietary technology designed to address functional mitral regurgitation in a minimally invasive manner.

Previous studies have established that the Carillon® therapy has caused a significant reduction in functional MR. This reduction in MR results in clinically significant improvements in exercise tolerance, quality of life, and thus overall function in a symptomatic heart failure population.

To supplement the findings from these previous studies, Cardiac Dimensions is conducting this post-market registry of the Carillon® Mitral Contour System® (CMCS) in patients with functional mitral regurgitation. This registry is a retrospective and prospective, multi-center, clinical registry designed to further characterize the acute and long-term safety and performance profile of the CMCS. Up to 250 implanted patients will be enrolled at up to 40 centers located in the European Union and countries that recognize the CE-mark as a valid marketing authorization.

Patients enrolled in the registry have received the Carillon implant and will be assessed to document the long-term safety and performance of the device. These patients will be followed according to routine standard of care post procedure follow up assessments.

• Study Type: Observational
• Enrollment (Anticipated): 250

Contacts and Locations

Study Locations

• Germany
  • Aachen, Germany
    • Universitätsklinikum Aachen
  • Ahaus, Germany
    • St. Marien Krankenhaus- Ahaus Vreden
  • Berlin, Germany
    • Sana Klinikum Lichtenberg
  • Bremen, Germany
    • Klinikum Links der Weser
  • Darmstadt, Germany
    • Kardiovaskular Zentrum Darmstadt
  • Dresden, Germany
    • Herzzentrum Dresden
  • Frankfurt, Germany
    • Cardiovascular center Frankfurt
  • Frankfurt, Germany
    • Universtitätsklinikum Frankfurt
  • Fritzlar, Germany
    • Hostpital zum Heiligen Geist
  • Hamburg, Germany
    • Asklepios Klinik Altona
  • Hamburg, Germany
    • Kath. Marienkrankenhaus GmbH- Hamburg
  • Hausham, Germany
    • Krankenhaus Agatharied GmbH
  • Kiel, Germany
    • Universitatsklinikum Schleswig-Holstein, Campus Kiel
  • Leipzig, Germany
    • Universitätsklinikum Leipzig
  • Mainz, Germany
    • Universitätsmedizin Mainz
  • Mannheim, Germany
    • Universitätsmedizin Mannheim
  • Neuss, Germany, 41464
    • Rheinland Klinikum Neuss GmbH- Lukaskrankenhaus
  • Ulm, Germany
    • Universitatsklinikum Ulm
  • Wiesbaden, Germany
    • Josefs Hospital Wiesbaden

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Up to 250 patients implanted with the Carillon implant.

Description

Inclusion Criteria:

1. Patients with functional mitral regurgitation (i.e., dilated cardiomyopathy), in accordance with CE-mark approved labeling
2. Patients implanted with the Carillon device
3. Patients must be ≥ 18 years old
4. Patients require informed consent prior to inclusion in this registry

5. Minimum baseline data, as described in CINCH Protocol, including:

   • Hemodynamic measures (by echocardiography)
   • Baseline must include the following measurements: MR grade, LVEF (%), LVEDD, LAD, and AP & ML diameters
   • NYHA Classification

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Other

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Prospective; "Prospective" patients are identified prior to undergoing the Carillon procedure and are only enrolled after being successfully implanted with the Carillon device (prior to hospital discharge). Prospective patients will have applicable medical history and details of the Carillon implant procedure collected from medical records. After the patient is discharged, the patient's primary care specialist (cardiologist) and clinical investigation site staff will coordinate follow-up evaluations. Patients will be evaluated at one (1), six (6), twelve (12) months per standard of care and with annual contact for an additional four (4) years, for a total of five (5) years to assess long-term safety of the Carillon implant.	Device: Carillon Mitral Contour System; The Cardiac Dimensions Carillon Mitral Contour System (CMCS) is a medical device and consists of the following components: A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV); A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly; A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation.; Other Names: Cardiac Dimensions; CMCS
Retrospective/Prospective; "Retrospective/Prospective" patients are implanted with the Carillon device and are currently being followed-up per standard of care. These patients will have applicable data collected from their medical records, including medical history, data about the Carillon procedure and follow-up visit data done since receiving the Carillon implant. They will be evaluated prospectively per standard of care follow-up through five (5) years post-implant to assess long-term safety of the Carillon implant.	Device: Carillon Mitral Contour System; The Cardiac Dimensions Carillon Mitral Contour System (CMCS) is a medical device and consists of the following components: A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV); A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly; A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation.; Other Names: Cardiac Dimensions; CMCS

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Death	All cause mortality including cardiovascular and non-cardiovascular death	6 months
Death	All cause mortality including cardiovascular and non-cardiovascular death	12 months
Death	All cause mortality including cardiovascular and non-cardiovascular death	24 months
Death	All cause mortality including cardiovascular and non-cardiovascular death	3 years
Death	All cause mortality including cardiovascular and non-cardiovascular death	4 years
Death	All cause mortality including cardiovascular and non-cardiovascular death	5 years
Serious adverse events	Number of procedure related or device related serious adverse events	6 months
Serious adverse events	Number of procedure related or device related serious adverse events	12 months
Change in New York Heart Association (NYHA) classification	Change in New York Heart Association (NYHA) Functional Classification at 6, 12, and 24 months, and 3, 4, and 5 years	6, 12, and 24 months, and 3, 4, and 5 years
Rate of Heart Failure Hospitalizations	Rate of hospitalization for heart failure	6 months
Rate of Heart Failure Hospitalizations	Rate of hospitalization for heart failure	12 months
Rate of Heart Failure Hospitalizations	Rate of hospitalization for heart failure	24 months
Rate of Heart Failure Hospitalizations	Rate of hospitalization for heart failure	3 years
Rate of Heart Failure Hospitalizations	Rate of hospitalization for heart failure	4 years
Rate of Heart Failure Hospitalizations	Rate of hospitalization for heart failure	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of MR Severity via Quantitative MR Variable: regurgitant volume (mL)	change in MR severity based in regurgitant volume as assessed by echocardiography in hospital, 6, 12, and 24 months, and 3, 4, and 5 years, in accordance with American Society of Echocardiography guidelines, compared to baseline.	6, 12, and 24 months, and 3, 4, and 5 years
Change of MR Severity via Quantitative MR Variable: regurgitant fraction (%)	change in MR severity based on regurgitant fraction (%) as assessed by echocardiography in hospital, 6, 12, and 24 months, and 3, 4, and 5 years, in accordance with American Society of Echocardiography guidelines, compared to baseline.	6, 12, and 24 months, and 3, 4, and 5 years
Change of MR Severity via Quantitative MR Variable: effective regurgitant orifice area (cm2 EROA)	change in MR severity based on effective regurgitant orifice area (cm2, EROA) as assessed by by Proximal Isovelocity Surface Area (PISA) via echocardiography in hospital, 6, 12, and 24 months, and 3, 4, and 5 years, in accordance with American Society of Echocardiography guidelines, compared to baseline.	6, 12, and 24 months, and 3, 4, and 5 years
Change of MR severity: Semi-Quantitative Parameter: Change in vena contract width	Change in vena contract width MR severity as assessed by echocardiography in hospital 6, 12, and 24 months, and 3, 4, and 5 years, in accordance with American Society of Echocardiography guidelines, compared to baseline.	6, 12, and 24 months, and 3, 4, and 5 years
Change of MR severity: Semi-Quantitative Parameter: Change in MV EVmax.	Change in MV EVmax MR severity as assessed by echocardiography in hospital, 6, 12, and 24 months, and 3, 4, and 5 years, in accordance with American Society of Echocardiography guidelines, compared to baseline.	6, 12, and 24 months, and 3, 4, and 5 years
Change of MR severity: Semi-Quantitative Parameter: Change in pulmonary vein flow.	Change in pulmonary vein flow MR severity as assessed by echocardiography in hospital, 6, 12, and 24 months, and 3, 4, and 5 years, in accordance with American Society of Echocardiography guidelines, compared to baseline.	6, 12, and 24 months, and 3, 4, and 5 years
Change in Left Atrial Area	Change in Left Atrial Area as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline	6, 12, and 24 months, and 3, 4, and 5 years
Change in Left Atrial Diameter	Change in Left Atrial Diameter as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline	6, 12, and 24 months, and 3, 4, and 5 years
Change in Left Atrial Volume Index	Change in Left Atrial Volume as assessed by echocardiography Index at 6, 12, and 24 months, and 3, 4, and 5 years over baseline	6, 12, and 24 months, and 3, 4, and 5 years
Change in Left Ventricular End Systolic Volume (LVESV)	Change in Left Ventricular End Systolic Volume (LVESV) as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline	6,12, and 24 months, and 3, 4, and 5 years
Change in Left Ventricular End Diastolic Volume (LVEDV)	Change in Left Ventricular End Diastolic Volume (LVEDV) as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline	6,12, and 24 months, and 3, 4, and 5 years
Change in Left Ventricular End Systolic Diameter (LVESD)	Change in Left Ventricular End Systolic Diameter (LVESD) as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline	6,12, and 24 months, and 3, 4, and 5 years
Change in Left Ventricular End Diastolic Diameter (LVEDD)	Change in Left Ventricular End Diastolic Diameter (LVEDD) as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline	6,12, and 24 months, and 3, 4, and 5 years
Change in Left Ventricular End Ejection Fraction (LVEF)	Change in Left Ventricular End Ejection Fraction (LVEF) as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline	6,12, and 24 months, and 3, 4, and 5 years
Change in exercise tolerance by walking	Change in exercise tolerance as measured by meters walked in Six Minute Walk Test at 6,12, and 24 months, and 3, 4, and 5 years over baseline	6,12, and 24 months, and 3, 4, and 5 years
Change in Quality-of-Life Overall Score	Change in Quality of Life (QoL) score, as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) at 6,12, and 24 months, and 3, 4, and 5 years over baseline	6,12, and 24 months, and 3, 4, and 5 years

Collaborators and Investigators

• Sponsor: Cardiac Dimensions, Inc.
• Investigators: Principal Investigator: Michael Haude, Prof. Dr., Rheinland Klinikum Neuss GmbH Lukaskrankenhaus

Study record dates

Study Major Dates

• Study Start (Actual): June 24, 2017
• Primary Completion (Anticipated): June 30, 2025
• Study Completion (Anticipated): June 30, 2030

Study Registration Dates

• First Submitted: October 20, 2022
• First Submitted That Met QC Criteria: December 28, 2022
• First Posted (Actual): January 10, 2023

Study Record Updates

• Last Update Posted (Actual): March 14, 2023
• Last Update Submitted That Met QC Criteria: March 13, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Keywords: Mitral Regurgitation; Functional Mitral Regurgitation; Cardiac Dimensions; Carillon Mitral Contour System; CINCH; CINCH FMR; Carillon; CMCS
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Valve Diseases; Mitral Valve Insufficiency
• Other Study ID Numbers: PMS-1681-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No plans for sharing

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes